ImaginAb Signs a Multi-Year Non-Exclusive License Agreement with Boehringer Ingelheim for CD8 ImmunoPET Technology

Shots:

• ImaginAb to receive license fees for providing ongoing technical, clinical, and regulatory support to facilitate the successful implementation of its CD8 ImmunoPET technology
• Following the new agreement, ImaginAb will supply clinical doses of 89Zr CD8 Immuno-PET technology to Boehringer Ingelheim for use in the clinical development of its novel oncology therapeutics throughout North America & the EU
• ImaginAb’s CD8 ImmunoPET technology enables quicker identification of drug efficacy & used for quantitative, non-invasive PET imaging of CD8 T cells in cancer patients

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Linkedin